
|Articles|February 6, 2006
FDA gives green light to anti-hepatitis B product
Advertisement
Cangene, one of Canada's largest biotechnology companies, announced that the FDA has approved HepaGam B for treatment following acute exposure to hepatitis B virus. HepaGam B is Cangene's hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the hepatitis B virus.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products
2
FDA Approves XFG-Targeted COVID-19 Vaccines From Multiple Companies
3
FDA Approves Stelara for Pediatric Ulcerative Colitis
4
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
5




























